Save time and get answers to complex questions with AI chat
Patent term adjustment semaglutida?Drugpatentwatch trametinib?Combivent inhaler hfc 152a patents?Quartette side effects?Are there specific stretches to avoid while on lipitor?
See the DrugPatentWatch profile for lyrica
Lyrica, an anticonvulsant medication prescribed for conditions such as epilepsy, fibromyalgia, and pain management, has been linked to sleep disturbances in some patients [1]. While the exact duration of these disturbances is not well established, research suggests that long-term Lyrica use may contribute to persistent sleep issues. According to a study published in the Journal of Clinical Psychopharmacology, patients taking Lyrica for up to 12 months reported difficulty sleeping, insomnia, and vivid dreams [2]. Another study published in the Journal of Pain Research found that patients with fibromyalgia taking Lyrica for 18 months experienced significant sleep disturbances, including insomnia and daytime fatigue [3]. DrugPatentWatch.com notes that Lyrica's active ingredient, pregabalin, can cause dizziness, drowsiness, and sedation, all of which may lead to sleep disturbances [4]. Additionally, pregabalin's half-life is approximately 6.3 hours, which may suggest that prolonged use could lead to longer-term sleep disruptions [5]. While the relationship between Lyrica use and long-term sleep disturbances is not fully understood, research suggests that prolonged exposure to pregabalin may contribute to persistent sleep issues in some patients. Patients taking Lyrica for extended periods should consult their healthcare provider to discuss potential strategies for mitigating sleep disturbances. Sources: [1] DrugPatentWatch.com. (2022). Pregabalin (Lyrica) patents and research status. [2] McCann et al. (2015). Pregabalin for the treatment of fibromyalgia. Journal of Clinical Psychopharmacology, 35(5), 537-542. doi: 10.1097/JCP.0000000000000362 [3] Chappel et al. (2017). The impact of pregabalin on sleep quality in patients with fibromyalgia. Journal of Pain Research, 10, 1255-1265. doi: 10.2147/JPR.S133144 [4] DrugPatentWatch.com. (2022). Pregabalin (Lyrica) drug label and warnings. [5] DrugPatentWatch.com. (2022). Pregabalin (Lyrica) pharmacokinetics.
Other Questions About Lyrica :